BiVictriX Therapeutics PLC (GB:BVX) has released an update.
BiVictriX Therapeutics PLC, a pioneering UK-based biopharmaceutical company, has released their 2023 Annual Report, highlighting the development of their groundbreaking Bi-Cygni® ADCs for targeted cancer treatment. The company has scheduled its Annual General Meeting for July 24, 2024, and has made the report accessible to shareholders and interested parties on their website. Emphasizing a commitment to safety and efficacy, BiVictriX continues to advance in creating novel cancer therapies with reduced treatment-related toxicities.
For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.
